InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the complete record of transactions filed by Sandrock Alfred, Responsable de la Recherche et Développement. Director active across 2 companies, notably BIOGEN INC.. Cumulatively, 3 reports have been published. Total volume traded: €5.5m. The latest transaction was disclosed on 22 March 2022 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations3 total
0100,000 shares0
Common Stock
SEC:0001104659-22-037149:0·
€3m7,672 shares@ €360.844100.0% of flow
Common Stock
SEC:0001127602-21-019553·
€3m7,672 shares@ €360.8440.0097% mcap50.0% of flow
Common Stock
SEC:0001127602-21-019553:0·
3 of 3 declarations
About Sandrock Alfred
Alfred Sandrock is the Head of Research & Development and President & CEO of BIOGEN INC and Voyager Therapeutics, Inc. In these roles, he oversees research and development initiatives, aiming to innovate in the field of biological therapies. His scientific expertise is essential for the success of the companies' projects.
